1. Pink Sheet
  3. >>Europe

‘Let's Be Ambitious,’ EMA Official Says Of Tackling GDPR Issues In Clinical Trials

 
• By Vibha Sharma

The EU clinical trials transformation initiative that was introduced this year could help address the issues clinical trial sponsors face with data privacy legislation, according to a senior EMA official.

Hands typing on laptop computer at table with double exposure of online security virtual interface. Concept of data protection and blockchain.
EU GDPR has strict requirements for protecting the personal data of clinical trial participants • Source: Shutterstock

A senior European Medicines Agency official has highlighted how the nine-month-old Accelerating Clinical Trials in the EU (ACT EU) initiative could serve as a platform to address the challenges clinical trial sponsors face in complying with EU data privacy requirements in the General Data Protection Regulation (GDPR).

The “momentum of ACT EU” initiative should be harnessed to drive efforts on this front, according to Peter Arlett, head...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By Joseph Haas

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.